Grail Raises $390M In Series D Financing To Advance Blood Cancer Test

Liquid biopsy company Grail raised $390m in a fourth round of financing, bringing the total funding to $1.9bn.

MT2005_Funding_298659794_1200.jpg

More from Business

More from Medtech Insight